Earnings Call · Q4 FY2022·2023-03-28

Q4 22EPS +33.33%·Rev n/aQ3 22EPS +9.33%·Rev n/aQ2 22EPS +5.48%·Rev n/aQ1 22EPS +2.94%·Rev n/a⚠ consensus missing

Whitehawk Therapeutics, Inc. WHWK

Marcy Graham — Investor Relations

Scott Giacobello — CFO and Interim President and CEO

Loretta Itri — Clinical/Medical Affairs

−5.5%1d on move date−5.3% vs SPY3d−1.9%5d+3.0%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more WHWK calls or request research access.

More WHWK calls Browse calls Request research access